Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Lopes, Renato D.; Macedo, Ariane Vieira Scarlatelli; Silva, Pedro Gabriel Melo de Barros e; Moll-Bernardes, Renata Junqueira; Feldman, Andre; D'Andréa Saba Arruda, Guilherme; Souza, Andrea Silvestre de; Albuquerque, Denilson Campos de; Mazza, Lilian; Santos, Mayara Fraga; Salvador, Natalia Zerbinatti; Gibson, C. Michael; Granger, Christopher B.; Alexander, John H.; Souza, Olga Ferreira de

Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Detalhes bibliográficos
Autor(a) principal:	Lopes, Renato D.
Data de Publicação:	2020
Outros Autores:	Macedo, Ariane Vieira Scarlatelli, Silva, Pedro Gabriel Melo de Barros e, Moll-Bernardes, Renata Junqueira, Feldman, Andre, D'Andréa Saba Arruda, Guilherme, Souza, Andrea Silvestre de, Albuquerque, Denilson Campos de, Mazza, Lilian, Santos, Mayara Fraga, Salvador, Natalia Zerbinatti, Gibson, C. Michael, Granger, Christopher B., Alexander, John H., Souza, Olga Ferreira de
Tipo de documento:	Artigo
Idioma:	eng
Título da fonte:	Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo:	https://www.arca.fiocruz.br/handle/icict/41422
Resumo:	Instituto D'Or de Pesquisa e Ensino. Rio de Janeiro, RJ, Brasil / Duke University Medical Center. Duke Clinical Research Institute. Durham, NC, USA / Brazilian Clinical Research Institute, São Paulo, SP, Brasil / Rede D'Or São Luiz, São Paulo, SP, Brasil.

Metadados do item

id	CRUZ_0956306124ba7e40d5ead036254c7bd4
oai_identifier_str	oai:www.arca.fiocruz.br:icict/41422
network_acronym_str	CRUZ
network_name_str	Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str	2135
spelling	Lopes, Renato D.Macedo, Ariane Vieira ScarlatelliSilva, Pedro Gabriel Melo de Barros eMoll-Bernardes, Renata JunqueiraFeldman, AndreD'Andréa Saba Arruda, GuilhermeSouza, Andrea Silvestre deAlbuquerque, Denilson Campos deMazza, LilianSantos, Mayara FragaSalvador, Natalia ZerbinattiGibson, C. MichaelGranger, Christopher B.Alexander, John H.Souza, Olga Ferreira de2020-05-27T15:47:20Z2020-05-27T15:47:20Z2020LOPES, Renato D. et al. Continuing Versus Suspending Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: Impact on Adverse Outcomes in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). American Heart Journal, p. 1-27, May 2020.0002-8703https://www.arca.fiocruz.br/handle/icict/4142210.1016/j.ahj.2020.05.002engElsevierContinuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleInstituto D'Or de Pesquisa e Ensino. Rio de Janeiro, RJ, Brasil / Duke University Medical Center. Duke Clinical Research Institute. Durham, NC, USA / Brazilian Clinical Research Institute, São Paulo, SP, Brasil / Rede D'Or São Luiz, São Paulo, SP, Brasil.Instituto D'Or de Pesquisa e Ensino. Rio de Janeiro, RJ, Brasil / Rede D'Or São Luiz. São Paulo, SP, Brasil / Santa Casa de São Paulo. São Paulo, SP, Brasil.Brazilian Clinical Research Institute, São Paulo, SP, Brasil.Instituto D'Or de Pesquisa e Ensino. Rio de Janeiro, RJ, Brasil.Instituto D'Or de Pesquisa e Ensino. Rio de Janeiro, RJ, Brasil / Rede D'Or São Luiz. São Paulo, SP, Brasil.Instituto D'Or de Pesquisa e Ensino. Rio de Janeiro, RJ, Brasil / Rede D'Or São Luiz. São Paulo, SP, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil / Instituto D'Or de Pesquisa e Ensino. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Rio de Janeiro, RJ, Brazil.Instituto D'Or de Pesquisa e Ensino. Rio de Janeiro, RJ, Brasil / Harvard Medical School, Boston, MA, USA.Brazilian Clinical Research Institute, São Paulo, SP, Brasil.Instituto D'Or de Pesquisa e Ensino. Rio de Janeiro, RJ, Brasil.Instituto D'Or de Pesquisa e Ensino. Rio de Janeiro, RJ, Brasil.Harvard Medical School, Boston, MA, USA.Duke University Medical Center. Duke Clinical Research Institute. Durham, NC, USA.Duke University Medical Center. Duke Clinical Research Institute. Durham, NC, USA.Instituto D'Or de Pesquisa e Ensino. Rio de Janeiro, RJ, Brasil / Rede D'Or São Luiz. São Paulo, SP, Brasil.Angiotensin-converting enzyme-2 (ACE2) may increase due to upregulation in patients using angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB). Because renin-angiotensin system blockers increase levels of ACE2, a protein that facilitates coronavirus entry into cells, there is concern that these drugs could increase the risk of developing a severe and fatal form of COVID-19. The impact of discontinuing ACEI and ARBs in patients with COVID-19 remains uncertain.DESIGNBRACE CORONA is a pragmatic, multicenter, randomized, phase IV, clinical trial that aims to enroll around 500 participants at 32 sites in Brazil. Participants will be identified from an ongoing national registry of suspected and confirmed cases of COVID-19. Eligible patients using renin-angiotensin system blockers (ACEI/ARBs) with a confirmed diagnosis of COVID-19 will be randomized to a strategy of continued ACEI/ARB treatment versus temporary discontinuation for 30 days. The primary outcome is the median days alive and out of the hospital at 30 days. Secondary outcomes include progression of COVID-19 disease, all-cause mortality, death from vascular causes, myocardial infarction, stroke, transient ischemic attack, new or worsening heart failure, myocarditis, pericarditis, arrhythmias, thromboembolic events, hypertensive crisis, respiratory failure, hemodynamic decompensation, sepsis, renal failure, troponin, B-type natriuretic peptide, N-terminal-pro hormone and D-dimer levels.SARS-CoV-2ACE InhibitorAngiotensin Receptor BlockerCoronavirusCOVID-19SimAhead of Printinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83132https://www.arca.fiocruz.br/bitstream/icict/41422/1/license.txt70425d8cb6e40fdcf4edd2ef0660b45bMD51ORIGINAL1-s2.0-S0002870320301381-main.pdf1-s2.0-S0002870320301381-main.pdfapplication/pdf4734347https://www.arca.fiocruz.br/bitstream/icict/41422/2/1-s2.0-S0002870320301381-main.pdfd3ed8514a186e1279ea1fb716e193c3fMD52TEXT1-s2.0-S0002870320301381-main.pdf.txt1-s2.0-S0002870320301381-main.pdf.txtExtracted texttext/plain43649https://www.arca.fiocruz.br/bitstream/icict/41422/3/1-s2.0-S0002870320301381-main.pdf.txte16baed2aee82134268d166c8467036cMD53icict/414222020-05-29 13:31:52.15oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352020-05-29T16:31:52Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv	Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
title	Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
spellingShingle	Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Lopes, Renato D. SARS-CoV-2 ACE Inhibitor Angiotensin Receptor Blocker Coronavirus COVID-19
title_short	Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
title_full	Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
title_fullStr	Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
title_full_unstemmed	Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
title_sort	Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
author	Lopes, Renato D.
author_facet	Lopes, Renato D. Macedo, Ariane Vieira Scarlatelli Silva, Pedro Gabriel Melo de Barros e Moll-Bernardes, Renata Junqueira Feldman, Andre D'Andréa Saba Arruda, Guilherme Souza, Andrea Silvestre de Albuquerque, Denilson Campos de Mazza, Lilian Santos, Mayara Fraga Salvador, Natalia Zerbinatti Gibson, C. Michael Granger, Christopher B. Alexander, John H. Souza, Olga Ferreira de
author_role	author
author2	Macedo, Ariane Vieira Scarlatelli Silva, Pedro Gabriel Melo de Barros e Moll-Bernardes, Renata Junqueira Feldman, Andre D'Andréa Saba Arruda, Guilherme Souza, Andrea Silvestre de Albuquerque, Denilson Campos de Mazza, Lilian Santos, Mayara Fraga Salvador, Natalia Zerbinatti Gibson, C. Michael Granger, Christopher B. Alexander, John H. Souza, Olga Ferreira de
author2_role	author author author author author author author author author author author author author author
dc.contributor.author.fl_str_mv	Lopes, Renato D. Macedo, Ariane Vieira Scarlatelli Silva, Pedro Gabriel Melo de Barros e Moll-Bernardes, Renata Junqueira Feldman, Andre D'Andréa Saba Arruda, Guilherme Souza, Andrea Silvestre de Albuquerque, Denilson Campos de Mazza, Lilian Santos, Mayara Fraga Salvador, Natalia Zerbinatti Gibson, C. Michael Granger, Christopher B. Alexander, John H. Souza, Olga Ferreira de
dc.subject.en.pt_BR.fl_str_mv	SARS-CoV-2 ACE Inhibitor Angiotensin Receptor Blocker Coronavirus COVID-19
topic	SARS-CoV-2 ACE Inhibitor Angiotensin Receptor Blocker Coronavirus COVID-19
description	Instituto D'Or de Pesquisa e Ensino. Rio de Janeiro, RJ, Brasil / Duke University Medical Center. Duke Clinical Research Institute. Durham, NC, USA / Brazilian Clinical Research Institute, São Paulo, SP, Brasil / Rede D'Or São Luiz, São Paulo, SP, Brasil.
publishDate	2020
dc.date.accessioned.fl_str_mv	2020-05-27T15:47:20Z
dc.date.available.fl_str_mv	2020-05-27T15:47:20Z
dc.date.issued.fl_str_mv	2020
dc.type.status.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv	info:eu-repo/semantics/article
format	article
status_str	publishedVersion
dc.identifier.citation.fl_str_mv	LOPES, Renato D. et al. Continuing Versus Suspending Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: Impact on Adverse Outcomes in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). American Heart Journal, p. 1-27, May 2020.
dc.identifier.uri.fl_str_mv	https://www.arca.fiocruz.br/handle/icict/41422
dc.identifier.issn.pt_BR.fl_str_mv	0002-8703
dc.identifier.doi.none.fl_str_mv	10.1016/j.ahj.2020.05.002
identifier_str_mv	LOPES, Renato D. et al. Continuing Versus Suspending Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: Impact on Adverse Outcomes in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). American Heart Journal, p. 1-27, May 2020. 0002-8703 10.1016/j.ahj.2020.05.002
url	https://www.arca.fiocruz.br/handle/icict/41422
dc.language.iso.fl_str_mv	eng
language	eng
dc.rights.driver.fl_str_mv	info:eu-repo/semantics/openAccess
eu_rights_str_mv	openAccess
dc.publisher.none.fl_str_mv	Elsevier
publisher.none.fl_str_mv	Elsevier
dc.source.none.fl_str_mv	reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ
instname_str	Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str	FIOCRUZ
institution	FIOCRUZ
reponame_str	Repositório Institucional da FIOCRUZ (ARCA)
collection	Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv	https://www.arca.fiocruz.br/bitstream/icict/41422/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/41422/2/1-s2.0-S0002870320301381-main.pdf https://www.arca.fiocruz.br/bitstream/icict/41422/3/1-s2.0-S0002870320301381-main.pdf.txt
bitstream.checksum.fl_str_mv	70425d8cb6e40fdcf4edd2ef0660b45b d3ed8514a186e1279ea1fb716e193c3f e16baed2aee82134268d166c8467036c
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5
repository.name.fl_str_mv	Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv	repositorio.arca@fiocruz.br
_version_	1813009282674720768

Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Registros relacionados